Maxim Group Reiterates Buy Rating for Joint (NASDAQ:JYNT)

Maxim Group restated their buy rating on shares of Joint (NASDAQ:JYNT) in a report published on Friday, AnalystRatings.com reports. The brokerage currently has a $25.00 price objective on the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

JYNT has been the subject of several other reports. ValuEngine lowered Joint from a buy rating to a hold rating in a report on Wednesday, October 2nd. B. Riley set a $23.00 price objective on Joint and gave the company a buy rating in a report on Friday, August 9th. DA Davidson reissued a buy rating on shares of Joint in a report on Monday, November 4th. Lake Street Capital increased their price objective on Joint from $20.00 to $30.00 and gave the company a buy rating in a report on Friday, August 9th. Finally, BidaskClub raised Joint from a buy rating to a strong-buy rating in a report on Thursday, September 19th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $24.17.

JYNT stock traded down $0.66 during trading on Friday, reaching $19.15. 459,700 shares of the stock were exchanged, compared to its average volume of 155,324. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 3.33. The firm has a market cap of $275.64 million, a P/E ratio of 478.75 and a beta of 1.01. The firm’s 50 day moving average is $18.82 and its 200 day moving average is $18.09. Joint has a twelve month low of $6.51 and a twelve month high of $21.80.

Joint (NASDAQ:JYNT) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.04 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.01. Joint had a return on equity of 114.93% and a net margin of 5.38%. The company had revenue of $12.73 million during the quarter, compared to the consensus estimate of $11.60 million. As a group, analysts predict that Joint will post 0.2 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Marshall Wace North America L.P. bought a new position in shares of Joint in the first quarter worth $47,000. Strs Ohio bought a new position in shares of Joint in the second quarter worth $63,000. Skylands Capital LLC boosted its holdings in shares of Joint by 4.4% in the second quarter. Skylands Capital LLC now owns 550,701 shares of the company’s stock worth $10,023,000 after acquiring an additional 23,051 shares during the period. Wedge Capital Management L L P NC bought a new position in shares of Joint in the second quarter worth $719,000. Finally, Wells Fargo & Company MN bought a new position in shares of Joint in the second quarter worth $227,000. 64.45% of the stock is owned by institutional investors and hedge funds.

Joint Company Profile

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.

Featured Article: Capital Gains

Analyst Recommendations for Joint (NASDAQ:JYNT)

Leave a Reply

Your email address will not be published. Required fields are marked *

*